Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy

Esmaeli, Bita; Hidaji, B S Lillie; Adinin, B R N Rosnie; Faustina, Misha; Coats, R N Carol; Arbuckle, Rebecca; Rivera, Edgardo; Valero, Vicente; Tu, Shi‐Ming; Ahmadi, M. Amir

doi:10.1002/cncr.11527

Cited by 84 publications

(84 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Myelosuppression was relatively mild, consistent with published literature suggesting that weekly docetaxel showed less neutropenia than triweekly administration. 37 Instead, as previously reported, 38,39 tearing and nail changes were persistent, troublesome toxicities. Particularly, the nail changes observed in this trial appeared to be more frequent and severe than those reported in previous trials of weekly docetaxel, 37,40 suggesting the possibility of synergism between weekly docetaxel and capecitabine in the development of nail toxicity.…”

Section: Discussionsupporting

confidence: 50%

Weekly Docetaxel in Combination With Capecitabine in Patients With Metastatic Gastric Cancer

Chun

Kim

Lee

et al. 2005

American Journal of Clinical Oncology

View full text Add to dashboard Cite

Docetaxel (T) and capecitabine (X) are active agents against gastric cancer with synergistic antitumor effects. We conducted the current phase II study to assess the response rate and toxicity of combination TX regimen in patients with metastatic gastric cancer. Eligible patients were treated with docetaxel (36 mg/m2 intravenously) on days 1 and 8 and capecitabine (1000 mg/m2 orally twice a day) on days 1-14 of a 3-week schedule until progression occurred. From December 2001 to May 2003, 55 patients with median age of 54 years (range, 22-73 years) were enrolled; 47 patients had measurable lesions. A total of 358 courses of treatment were given, with a median of 5 (range, 1-22+) per patient. Objective responses were documented in 19 of 47 patients with measurable lesions (response rate, 40.4%; 95% confidence interval [CI], 25.9-54.9), with the median response duration of 5.6 months (range, 2.1-13.6+). At a median follow up of 15.9 months for all of 55 study patients, the median time to progression and survival were 4.5 months (95% CI, 3.4-5.6) and 12.0 months (95% CI, 7.5-16.6), respectively. Hematologic toxicities were mild to moderate, and the observed grade 3 nonhematologic toxicities, the most frequent of which was stomatitis, were generally manageable. Four patients experienced pneumonitis, but all of them responded to steroid treatment. The TX regimen was relatively well tolerated and effective against metastatic gastric cancer, with the added advantage of being an outpatient regimen.

show abstract

Section: Discussionsupporting

confidence: 50%

Weekly Docetaxel in Combination With Capecitabine in Patients With Metastatic Gastric Cancer

Chun

Kim

Lee

et al. 2005

American Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Esmaeli et al (26) from MD Anderson Cancer Center reported on 148 patients with this type of side effect. Thirty of 71 patients given weekly docetaxel needed surgery to correct epiphora.…”

Section: Discussionmentioning

confidence: 99%

“…3) and for other chemo side effects from 11.4 to 20.7. The global quality of life (QLQ-C30) was significantly associated with gastrointestinal side effects and the attitude towards disease at baseline and after the first course of chemotherapy, but changed during treatment to neurological [25][26][27][28] side effects and other side effects related to chemotherapy in addition to gastrointestinal side effects all measured on the QLQ-OV28 scale (Fig. 4).…”

Section: Quality-of-lifementioning

confidence: 99%

A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: Neurological toxicity and quality-of-life evaluation

Sorbe

Graflund²,

Nygren³

et al. 2011

Int J Oncol

View full text Add to dashboard Cite

Abstract. The purpose of this study was to assess the response rate, toxicity, progression-free survival (PFS) and overall survival (OS) in a series of advanced stage ovarian carcinoma patients treated with a first-line weekly docetaxel and three weekly carboplatin regimens. All eligible patients were treated with intravenous docetaxel (30 mg/m 2 ) on Days 1, 8 and 15, and carboplatin (area under the curve, 5) on Day 1; Q21 days for at least 6 cycles. Neurological tests, questionnaires, and the EORTC QLQ-C30 and OV28 were used for quality-of-life assessments. One hundred and six patients received at least one cycle of primary chemotherapy (median 6.0; range, 1-9) and they were evaluable for toxicity assessment. Eighty-five patients had evaluable disease and received at least 3 courses of chemotherapy and were evaluable for clinical response rate. The overall response rate was 78.8% (95% CI 70.1-87.5%) and the biochemical response was 92.8% (95% CI 87.2-98.4%). The median PFS was 12.0 months and the median OS was 35.3 months. Thirty-six patients (34.0%) experienced grades 3 and 4 neutropenia, which resulted in the removal of 3 patients. Six patients (5.7%) experienced grades 3 or 4 thrombocytopenia. No patients experienced grade 3-4 sensory neuropathy. Epiphora, nail changes and fatigue were frequently recorded non-hematological side effects. The tolerable hematological toxicity (no need for colony-stimulating factors) and the low rate of severe neurotoxicity (only grade 1-2) and response rates in line with the standard 3-week paclitaxel-carboplatin regimen for advanced primary ovarian carcinoma after suboptimal cytoreductive surgery make this regimen an interesting alternative in selected patients.

show abstract

“…Nail changes are more common with the weekly schedule than with the every-21-day schedule (37% vs 30%, respectively) (Tannock et al 2004). Grade 3 and grade 4 blockage of the lacrimal drainage apparatus causing excessive tearing occurred in 0.6% in the TAX 327 study, but Esmaeli and colleagues reported this as a more common occurrence with the weekly schedule (Esmaeli et al 2003). Excessive eye tearing should be monitored and prompt intervention is imperative.…”

Section: Toxicities Associated With Docetaxel As Reported In the Tax3mentioning

confidence: 99%

Docetaxel treatment in the elderly patient with hormone refractory prostate cancer

Sinibaldi¹

2008

CIA

View full text Add to dashboard Cite

Docetaxel is an anti-microtubular agent in the family of the taxanes, now FDA approved as fi rst line chemotherapy for the treatment of hormone refractory metastatic prostate cancer. Recent data from two large randomized Phase III trials showed a survival advantage in hormone refractory prostate cancer patients treated with docetaxel. This discovery changed the perceptions about utilization of chemotherapy for this devastating disease and introduced a new paradigm/standard of care treatment for this patient population. The management of elderly patients with metastatic prostate cancer is an important issue because according to data from the Surveillance, Epidemiology, and End Results (SEER) program, the American Cancer Society, and the United Nations, the incidence of prostate cancer in elderly men is expected to increase since people are living longer. In this paper we will review the results of trials evaluating docetaxel in hormone refractory prostate cancer and the implications of these trials as they relate to diagnosis and management of this disease in the elderly man.

show abstract

Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy

Cited by 84 publications

References 11 publications

Weekly Docetaxel in Combination With Capecitabine in Patients With Metastatic Gastric Cancer

Weekly Docetaxel in Combination With Capecitabine in Patients With Metastatic Gastric Cancer

A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: Neurological toxicity and quality-of-life evaluation

Docetaxel treatment in the elderly patient with hormone refractory prostate cancer

Contact Info

Product

Resources

About